Dr Barbara Pistilli discusses the case of Marie T., a patient with pretreated HR+/HER2- (IHC 0) metastatic breast cancer (mBC) who has developed endocrine resistance.

 

The key question: What are the next therapeutic options for patients like Marie T.? 

 

In this case-based video, we follow Marie T.’s clinical journey—from diagnosis and treatment to managing adverse events (AEs).  

 

In this video, Dr Pistilli explores: 

  • The mechanism of action of antibody–drug conjugates (ADCs) 
  • Currently available ADCs for HR+/HER2- mBC
  • Strategies for managing ADC-associated AEs 

 

Clinical takeaways

  • Endocrine-resistant HR+/HER2− mBC remains a significant unmet need, and ADCs offer a more effective and tolerable later-line alternative to conventional chemotherapy.
  • Dato-DXd demonstrated a statistically significant and clinically meaningful improvement in PFS versus chemotherapy, with continued benefits across secondary efficacy and PRO endpoints, despite OS not reaching statistical significance—potentially influenced by post-progression ADC use.
  • Sacituzumab govitecan remains a valuable treatment option for heavily pretreated patients with HR+/HER2− breast cancer, demonstrating clinically meaningful improvements in PFS, OS, and PRO, with a manageable safety profile when supported by appropriate care.
  • To support treatment adherence and maintain QoL with ADCs, effective management of AEs is crucial—whether through prophylaxis, supportive medications, interventions, and/or dose modifications.
  • In the absence of predictive biomarkers, selection of ADCs for HR+/HER2− (IHC0) mBC should be guided by prior treatments, clinical characteristics, toxicity profiles, and patient preferences.
  • Recognise the efficacy and safety profiles of TROP2-directed ADCs for patients with advanced or metastatic HR+/HER2- BC, and their place in the treatment landscape
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to monitor and manage adverse events associated with ADC therapy 

Barbara Pistilli, MD is the chair of the breast cancer unit at Gustave Roussy since March 2021. The clinical activity of Breast Cancer Group encloses around 2000 new patients and 700 inclusions in clinical trials, yearly. The goal of the group is to provide groundbreaking and patient-centered strategies that cover all steps from breast cancer prevention to development of innovative treatment strategies and survivorship care. The scientific strategy is driven by the integration between translational and clinical sciences in a limited number of large comprehensive programs, where knowledge in biology drives clinical development and patient samples feed translational research. In this regard, she leads a large translational program focusing on identification of mechanisms of response and resistance to antibody drug conjugates which include a number of phase I and II trials based on diverse treatment strategies in patients with metastatic breast and lung cancer, with a large sample collection for exploratory biomarker analysis.

Dr Barbara Pistilli has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Seagen, Gilead, Novartis, Lilly, MSD, Pierre Fabre, Daiichi Sankyo, Olema and Pfizer

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock 1 MIN
  • calendar May 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA